ARS Pharmaceuticals
SPRY
SPRY
150 hedge funds and large institutions have $928M invested in ARS Pharmaceuticals in 2024 Q3 according to their latest regulatory filings, with 48 funds opening new positions, 58 increasing their positions, 23 reducing their positions, and 12 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
150
Holders Change
+35
Holders Change %
+30.43%
% of All Funds
2.17%
Holding in Top 10
3
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+50%
% of All Funds
0.04%
New
48
Increased
58
Reduced
23
Closed
12
Calls
$14.2M
Puts
$9.25M
Net Calls
+$4.98M
Net Calls Change
-$13.4M
Top Buyers
| 1 |
WP
1
Woodline Partners
San Francisco,
California
|
$14.3M |
| 2 |
FTM
2
First Turn Management
Del Mar,
California
|
$8.6M |
| 3 |
DFO
3
Duquesne Family Office
New York
|
$7.79M |
| 4 |
4
Morgan Stanley
New York
|
$9.26M |
| 5 |
5
Millennium Management
New York
|
$7.06M |
